A PHASE 2a, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1273 SARS-COV-2 VACCINE IN ADULTS AGED 18 YEARS A

Administered By

Surgery, Surgical Sciences

Awarded By

Moderna Therapeutics, Inc.

Contributors

Beerman, Rebecca Clinical Data Manager
Montefiori, David Charles Principal Investigator
Sarzotti-Kelsoe, Marcella Director
Shen, Xiaoying Co Investigator

Start/End

May 1, 2021 - June 30, 2022